Abstract
Given the high prevalence of the atherogenic forms of apolipoprotein B (apoB) dyslipoproteinemias and the effectiveness of appropriate therapy, we feel that access for all physicians to simple, effective diagnostic aids that enable use of widely available technology is vitally important in clinical lipidology. In this Review, therefore, we present a diagnostic algorithm for the diagnosis of these disorders that is based on concentrations of total cholesterol, triglyceride and apoB. By including apoB values, lipoprotein number and composition can be deduced and each of the classic dyslipoproteinemias identified. All three parameters can be accurately and inexpensively determined in clinical laboratories and, therefore, this algorithm can be used by any physician to make an accurate diagnosis without use of specialist research laboratories. Just as the application of LDL cholesterol measurement moved clinical practice forward from plasma lipids to lipoprotein lipids, we believe that the use of apoB will further advance diagnosis and treatment of dyslipoproteinemias.
Key Points
-
Given the high prevalence of the atherogenic forms of apolipoprotein B (apoB) dyslipoproteinemias and the effectiveness of appropriate therapy, effective diagnostic aids are vitally important in clinical lipidology
-
LDL particles are heterogeneous in composition and, therefore, measurement of serum LDL cholesterol concentrations could underestimate the LDL particle number
-
We have created an algorithm based on total cholesterol, triglyceride and apoB levels; the inclusion of apoB enables the number and composition of lipoproteins to be deduced, and thereby the subtype of apoB dyslipoproteinemia to be identified
-
LDL make up the majority of atherogenic particles in plasma, each containing one molecule of apoB and, therefore, apoB level is determined by LDL particle number
-
All three parameters can be accurately and inexpensively determined in clinical laboratories and, therefore, this algorithm can be used by any physician to make an accurate diagnosis without use of specialist research laboratories
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fredrickson DS et al. (1967) Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med 276: 273–281
Friedewald WT et al. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502
Bachorik PS and Ross JW, and The National Cholesterol Education Program Working Group on Lipoprotein Measurement (1995) National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 41: 1414–1420
Rubins HB et al. (1995) Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 75: 1196–1201
Goldstein JL et al. (1973) Hyperlipidaemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidaemia. J Clin Invest 52: 1544–1568
Brunzell JD et al. (1976) Myocardial infarction in the familial forms of hypertriglyceridemia. Metab Clin Exp 25: 313–320
Barter PJ et al. (2006) ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259: 247–258
Alaupovic P (2003) The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 5: 459–467
Brunzell JD et al. (2008) Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811–822
Brunzell JD et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512–1524
Sigurdsson G et al. (1992) Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 69: 1251–1254
Cremer P et al. (1997) Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 129: 221–230
Sweetnam PM et al. (2000) Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Euro J Clin Invest 30: 947–956
Wald NJ et al. (1994) Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343: 75–79
Lamarche B et al. (1996) Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 94: 273–278
Held C et al. (1997) Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). Atherosclerosis 135: 109–118
Pedersen TR et al. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 97: 1453–1460
Ruotolo G et al. (1998) Treatment effects on serum lipoprotein lipids, apolipoproteins, a low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 32: 1648–1656
Moss AJ et al. (1999) Thrombogenic factors and recurrent coronary events. Circulation 99: 2517–2522
Gotto AM et al. (2000) Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101: 477–484
van Lennep JER et al. (2000) Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20: 2408–2413
Walldius G et al. (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026–2033
Talmud PJ et al. (2002) Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22: 1918–1923
Simes RJ et al. (2002) Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105: 1162–1169
Blake GJ et al. (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930–1937
Kuller L et al. (2002) Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22: 1175–1180
Vakkilainen J et al. (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease in the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107: 1733–1737
Shai I et al. (2004) Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 110: 2824–2830
Jiang R et al. (2004) Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27: 1991–1997
Corsetti JP et al. (2004) Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 177: 367–373
Pischon T et al. (2005) Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112: 3375–3383
St-Pierre AC et al. (2006) Apolipoprotein-B, low-density lipoprotein cholesterol, and long-term risk of coronary heart disease in men. Am J Cardiol 97: 997–1001
Ridker PM et al. (2005) Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294: 326–333
Meisinger C et al. (2005) Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 26: 271–278
Bruno G et al. (2006) Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato Study. Diabetologia 49: 937–944
Hsia SH et al. (2006) A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 98: 1047–1052
Otvos JD et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556–1563
Stettler C et al. (2006) Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. J Intern Med 260: 272–280
Benn M et al. (2007) Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 27: 661–670
Chien KL et al. (2007) Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 48: 2499–2505
Ingelsson E et al. (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298: 776–785
Cromwell WC et al. (2007) LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. J Clin Lipidol 1: 583–592
Onat A et al. (2007) Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks [Turkish]. Anadolu Kardiyol Derg 7: 128–133
Kastelein JJP et al. (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117: 3002–3009
McQueen MJ et al. (2008) Lipids, lipoproteins, and apolipoproteins as risk markers associated with myocardial infarction in 52 countries (the INTERHEART Study): a case–control study. Lancet 372: 224–233
Holme I et al. (2008) Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Ann Med 8: 1–9
El Harchaoui K et al. (2007) Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women. J Am Coll Cardiol 49: 547–553
Frontini MG et al. (2008) Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 121: 924–929
Holme I et al. (2008) Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein Mortality Risk Study (AMORIS). J Intern Med 264: 30–38
Sniderman AD et al. (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 361: 777–780
Simon A et al. (2005) Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179: 339–344
Juonala M et al. (2008) Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood. The Cardiovascular Risk in Young Finns Study. J Am Coll Cardiol 52: 293–299
Tabas I et al. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116: 1832–1844
Sniderman A et al. (2007) Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clinical Lipidol 1: 256–263
Bjornheden T et al. (1996) Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123: 43–56
Hurt-Camejo E et al. (1990) Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 31: 1387–1398
de Graaf J et al. (1991) Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol 11: 298–306
Jungner I et al. (2006) Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 97: 943–946
Mora S et al. (2007) LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192: 211–217
Veerkamp MJ et al. (2004) Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 109: 2980–2985
Sniderman AD et al. (2002) A proposal to redefine familial combined hyperlipidaemia—third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 32: 71–73
Sniderman AD and Couture P (2008) Therapeutic Strategies in Cardiovascular Risk, 101–108 (Eds Graham IM and D-Agostino RB). Oxford: Clinical Publishing
Tremblay AJ et al. (2007) Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort. Clin Biochem 40: 25–29
Genest J Jr et al. (1993) Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb Vasc Biol 13: 1728–1737
Sniderman AD et al. (1999) Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis 148: 215–229
ter Avest E et al. (2007) Effect of aging and obesity on the expression of dyslipidemia in children from families with familial combined hyperlipidemia. Clin Sci 112: 131–139
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
de Graaf, J., Couture, P. & Sniderman, A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 4, 608–618 (2008). https://doi.org/10.1038/ncpendmet0982
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0982
This article is cited by
-
Apolipoproteins in vascular biology and atherosclerotic disease
Nature Reviews Cardiology (2022)
-
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Cardiovascular Drugs and Therapy (2013)
-
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Nature Reviews Endocrinology (2010)